EntrolyticsMD, the world's first imaging platform for digestive diseases has been listed with the FDA.
Entrolytics is used across now hundreds of research projects and many of the upcoming Phase III and IV clinical trials for IUS and MRE.
FDA Listing brings the technology to the clinic and as a platform for a new generation of GI imaging tools.
For more information on Entrolytics contact us: info@motilent.io
🗞 News
🥳✨ vEUA Version 2.0 for better markup of perianal fistula
✈️ 🇺🇸 Motilent will be attending RSNA! Click here to book a meeting with the team
📢 💡 GIQuant is now LIVE across Northern Care Alliance Hospitals!
NCA is formed of Bury, Oldham, Rochdale & Salford Hospitals in Greater Manchester.
📝🇺🇸 EntrolyticsMD is ready for clinical use!
👁 ⬇️
vEUA’s new features include modifications to allow visualisation of distorted anal canals, intersphincteric fistulas and scope to annotate other anatomy. Improving vEUA will enhance communication between radiologists, surgeons and patients leading to better patient outcomes.
For a demo email us at: info@motilent.io
🔗 From socials
💊 The absorption of oral medications is influenced by both the drug itself and the specific anatomy and physiology of an individual's gastrointestinal (GI) tract. While we typically evaluate these factors in healthy adults during drug development, it’s vital to recognise that many factors might alter the GI tract and its ability to absorb drugs.
Motilent at UEGW:
Imaging Scientist Iyad Naim and Senior Software Engineer Benjamin Barrow alongside scientific poster results at UEG Week 2023
PP0743: Magnetic Resonance Imaging-based Measure of Fibrosis in Enteric Crohn’s Disease (MERIT)
The MERIT study plays a crucial role in validating several imaging biomarkers, Magnetisation Transfer (MT), T2-weighted bowel wall mean signal intensity, DWI, quantified T1, and T2 measurements). However, here we show simple T2 over the volume correlated with fibrosis and may be more reliable in clinical practice.
PP0744: Semi-Automated Segmentation of Inflamed Bowel Wall on Noncontrast T2-Weighted MRI for Streamlined Volumetric Assessment of Crohn’s Disease
Bowel wall thickness changes by mm. Bowel wall volume should change by many mm3 but it's completely impractical to do manually. The “Semi-automated segmentation of inflamed bowel wall on non-contrast T2-weighted MRI” project addresses a crucial need in CD management. Accurate assessment of CD activity is essential for effective treatment.
The goal here is to bring together a quick round up of interesting content, news and imagery relevant to - and I know this sounds oddly specific - the non-invasive IBD community with occasional forays into the mechanistic elements of diseases featuring GI problems (e.g. Cystic Fibrosis, Parkinson's, gastroparesis etc).
Feedback is very welcome, especially around hot topics in the industry and might even make it into a future newsletter. If there are any community messages that need passing along (jobs, studies, points of interest etc) we’re happy to communicate them here.
And lastly - if you know anyone in the space, please forward this on and encourage them to subscribe.
Alex Menys, CEO & Honorary Associate Prof at UCL